Anna Godsmark
Impact in
- Infectious Diseases top 5%
- SARS-CoV-2 and COVID-19 Research
- SARS-CoV-2 detection and testing
- COVID-19 Clinical Research Studies
- Modeling and Simulation top 10%
- COVID-19 epidemiological studies
Papers in
-
- SARS-CoV-2 and COVID-19 Research 8
- COVID-19 Clinical Research Studies 1
-
- COVID-19 epidemiological studies 3
- Journals
- Nature Communications (5 papers)Nature Microbiology (1 paper)Clinical Infectious Diseases (1 paper)Nature Medicine (1 paper)Scientific Reports (1 paper)
- Partner nations
- United Kingdom
In The Last Decade
Anna Godsmark
9 papers receiving 593 citations
Anna Godsmark's Hit Papers
Peers
Comparison fields: 5 of 48
- Infectious Diseases 514
- Modeling and Simulation 27
- Neurology 18
- Immunology 18
- Applied Microbiology and Biotechnology 2
Countries citing papers authored by Anna Godsmark
This map shows the geographic impact of Anna Godsmark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Godsmark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Godsmark more than expected).
Fields of papers citing papers by Anna Godsmark
This network shows the impact of papers produced by Anna Godsmark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Godsmark. The network helps show where Anna Godsmark may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 245 | |
| 2 | Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines Hit paper breakdown → | 2022 | 159 |
| 3 | 2021 | 88 | |
| 4 | 2024 | 39 | |
| 5 | 2021 | 30 | |
| 6 | 2023 | 23 | |
| 7 | 2022 | 12 | |
| 8 | 2024 | 5 | |
| 9 | 2023 | 4 |
About Anna Godsmark
Anna Godsmark is a scholar working on Infectious Diseases, Modeling and Simulation, Health, Statistics and Probability and Nuclear Energy and Engineering, having authored 9 papers that have together received 605 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (8 papers), COVID-19 epidemiological studies (3 papers), COVID-19 Clinical Research Studies (1 paper), Vaccine Coverage and Hesitancy (1 paper) and Statistical Methods in Epidemiology (1 paper). The work is most often cited by research in Infectious Diseases (514 citations), Modeling and Simulation (27 citations), Neurology (18 citations), Immunology (18 citations) and Applied Microbiology and Biotechnology (2 citations). Anna Godsmark has collaborated with scholars based in United Kingdom. Their work appears in journals such as Nature Communications, Nature Microbiology, Clinical Infectious Diseases, Nature Medicine and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.